CO5640146A2 - Complejos de cristales de proteina y polimeros ionicos - Google Patents

Complejos de cristales de proteina y polimeros ionicos

Info

Publication number
CO5640146A2
CO5640146A2 CO05073929A CO05073929A CO5640146A2 CO 5640146 A2 CO5640146 A2 CO 5640146A2 CO 05073929 A CO05073929 A CO 05073929A CO 05073929 A CO05073929 A CO 05073929A CO 5640146 A2 CO5640146 A2 CO 5640146A2
Authority
CO
Colombia
Prior art keywords
factors
hormones
proteins
hormone
group
Prior art date
Application number
CO05073929A
Other languages
English (en)
Inventor
Nazer Khalaf
Chandrika Govardhan
Original Assignee
Altus Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altus Pharmaceutical Inc filed Critical Altus Pharmaceutical Inc
Publication of CO5640146A2 publication Critical patent/CO5640146A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

1.- Un complejo que comprende un cristal de proteína y uncompuesto iónico.2.- El complejo de acuerdo con la reivindicación 1, en donde dicha proteína se selecciona del grupo que consiste de: proteínas terapéuticas, proteínas de fusión, glicoproteínas, receptores, antígenos sintéticos, antígenos recombinantes, proteínas de superficie viral, hormonas, anticuerpos, enzimas, fragmentos Fab, péptidos cíclicos, péptidos lineales.3.- El complejo de acuerdo con la reivindicación 2, en donde dicha proteína terapéutica se selecciona del grupo que consiste de: péptido 1 similar glucagon, anticuerpos, antígenos de histocompatibilidad, integrinas, selectinas, inhibidores, factores de crecimiento, hormonas postridicales, hormonas de crecimiento nervioso, factores de coagulación sanguínea, moléculas de adhesión, proteínas morfogénicas de hueso, lectinas, factores trópicos, citoquinas tales como TGF-ß, IL-2, IL-4, a-IFN, ß -IFN, ?-IFN, TNF, IL-6, IL-8, linfotoxina, IL-5, factor de inhibición de migración, GMCSF, IL-7, IL-3. factores de estimulación de colonia macrofága-monocito, factores de estimulación de colonia granulocito, proteínas de resistencia multidroga, otras linfoquinas, toxoides, eritropoyetina, factor VIII, amilina, TPA, dornasa-a, a-1-antitripsina, hormonas de crecimiento humano, hormonas de crecimiento nervioso, proteínas morfogénicas de hueso, factores de diferenciación de crecimiento, neuregulina, ureasa, y toxoides.4.- El complejo de acuerdo con la reivindicación 2, en donde dicha hormona se selecciona del grupo que consiste de: hormona de crecimiento humano, glucagones, hormona paratiroide, hormonas de fertilidad, hormona lutenizante y hormona de estimulación del folículo.5.- El complejo de acuerdo con la reivindicación 2, en donde dicho anticuerpo se selecciona del grupo que consiste de: Infliximab, Etanercept, Rituximab, trastuzumab, Abciximab, Palivizumab, Murumonab-CD3, Gemtuzumab, Basiliximab, Daclizumab, Zevalin y Milotarg.
CO05073929A 2002-12-31 2005-07-27 Complejos de cristales de proteina y polimeros ionicos CO5640146A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43777502P 2002-12-31 2002-12-31

Publications (1)

Publication Number Publication Date
CO5640146A2 true CO5640146A2 (es) 2006-05-31

Family

ID=32713227

Family Applications (1)

Application Number Title Priority Date Filing Date
CO05073929A CO5640146A2 (es) 2002-12-31 2005-07-27 Complejos de cristales de proteina y polimeros ionicos

Country Status (12)

Country Link
US (1) US20060008532A1 (es)
EP (1) EP1585771A4 (es)
JP (2) JP2006523609A (es)
KR (1) KR20050094832A (es)
AU (1) AU2003300126B2 (es)
BR (1) BR0317896A (es)
CA (1) CA2512001A1 (es)
CO (1) CO5640146A2 (es)
MX (1) MXPA05007182A (es)
NZ (2) NZ571243A (es)
WO (1) WO2004060920A1 (es)
ZA (1) ZA200505306B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541606B2 (en) * 1997-12-31 2003-04-01 Altus Biologics Inc. Stabilized protein crystals formulations containing them and methods of making them
US20060177416A1 (en) 2003-10-14 2006-08-10 Medivas, Llc Polymer particle delivery compositions and methods of use
DK1581251T3 (da) 2002-12-31 2016-06-27 Althea Tech Inc Krystaller af humant væksthormon og fremgangsmåder til fremstilling deraf
US8728525B2 (en) 2004-05-12 2014-05-20 Baxter International Inc. Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
EP1928551B1 (en) * 2005-06-10 2012-05-30 Althea Technologies, Inc. Methods to reduce oxalate concentration by administration of oxalate oxidase crystals
ATE501248T1 (de) * 2005-07-02 2011-03-15 Arecor Ltd Stabile wässrige systeme mit proteinen
CA2623239C (en) * 2005-09-22 2016-07-12 Medivas, Llc Solid polymer delivery compositions and methods for use thereof
CA2623198C (en) 2005-09-22 2014-08-05 Medivas, Llc Bis-(a-amino)-diol-diester-containing poly(ester amide) and poly(ester urethane) compositions and methods of use
LT1965823T (lt) * 2005-11-04 2016-10-10 Glaxosmithkline Llc Hipoglikeminių agentų skyrimo būdai
US20070134332A1 (en) * 2005-11-21 2007-06-14 Medivas, Llc Polymer particles for delivery of macromolecules and methods of use
EP1962894A4 (en) * 2005-12-07 2012-11-14 Medivas Llc PROCESS FOR ASSEMBLING A BIOLOGICAL POLYMER-AGENT DELIVERY COMPOSITION
CA2634053A1 (en) * 2005-12-23 2007-07-05 Altus Pharmaceuticals Inc. Compositions comprising polycation-complexed protein crystals and methods of treatment using them
WO2007102946A2 (en) * 2006-01-23 2007-09-13 Amgen Inc. Crystalline polypeptides
WO2007130477A2 (en) * 2006-05-02 2007-11-15 Medivas, Llc Delivery of ophthalmologic agents to the exterior or interior of the eye
WO2007133616A2 (en) * 2006-05-09 2007-11-22 Medivas, Llc Biodegradable water soluble polymers
US7964574B2 (en) 2006-08-04 2011-06-21 Baxter International Inc. Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes
CA2672284C (en) 2006-12-18 2014-08-26 Altus Pharmaceuticals Inc. Human growth hormone formulations
EP2120859B1 (en) * 2006-12-21 2013-11-20 Stryker Corporation Sustained-release formulations comprising bmp-7 crystals
WO2008150929A1 (en) * 2007-05-29 2008-12-11 Manhattan Pharmaceuticals, Inc. Topical compositions comprising a macromolecule and methods of using same
CA2709412A1 (en) * 2007-07-24 2009-01-29 Medivas, Llc Biodegradable cationic polymer gene transfer compositions and methods of use
DK2215117T4 (en) 2007-10-30 2018-04-09 Genentech Inc ANTISTO PURIFICATION BY CATION CHANGE CHROMATOGRAPHY
US20110171268A1 (en) * 2008-03-24 2011-07-14 Althea Technologies, Inc. Uricase compositions and methods of use
CA2733686A1 (en) * 2008-08-13 2010-02-18 Medivas, Llc Aabb-poly(depsipeptide) biodegradable polymers and methods of use
US8323615B2 (en) 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing multi-phasic dispersions
US8323685B2 (en) 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing compositions containing microparticles
US8367427B2 (en) 2008-08-20 2013-02-05 Baxter International Inc. Methods of processing compositions containing microparticles
JP5119232B2 (ja) * 2009-11-06 2013-01-16 株式会社マルハニチロ食品 プロタミンの定量法
JP5808082B2 (ja) * 2010-04-30 2015-11-10 株式会社Adeka 細胞への水溶性高分子量物質の導入方法及び導入剤
JP5703617B2 (ja) * 2010-07-23 2015-04-22 ライオン株式会社 口臭消臭製剤
MX347014B (es) * 2010-11-24 2017-04-07 Durect Corp Composición para administración de fármaco biodegradable.
US9873765B2 (en) 2011-06-23 2018-01-23 Dsm Ip Assets, B.V. Biodegradable polyesteramide copolymers for drug delivery
WO2012175746A1 (en) 2011-06-23 2012-12-27 Dsm Ip Assets B.V. New biodegradable polyesteramide copolymers for drug delivery
EP2782590A4 (en) * 2011-11-23 2016-08-03 Durect Corp BIODEGRADABLE AND MEDIUM-RADIATED STERILIZED MEDICAMENTAL COMPOSITIONS
US8822423B2 (en) * 2012-05-17 2014-09-02 Janssen Biotech, Inc. Affinity peptides toward infliximab
GB201314452D0 (en) * 2013-08-13 2013-09-25 Ostara Biomedical Ltd Embryo implantation
EP3064213A4 (en) * 2013-10-28 2017-04-26 Terumo Kabushiki Kaisha Protein aqueous suspension
JP6564369B2 (ja) 2013-12-09 2019-08-21 デュレクト コーポレイション 薬学的活性剤複合体、ポリマー複合体、ならびにこれらを伴う組成物及び方法
GB201409451D0 (en) 2014-05-28 2014-07-09 Ipabc Ltd Antimicrobial preparations, methods for preparing the same and uses thereof to combat microorganisms
AU2015366355B2 (en) 2014-12-18 2020-05-28 Dsm Ip Assets B.V. Drug delivery system for delivery of acid sensitive drugs
GB201501302D0 (en) 2015-01-27 2015-03-11 Ostara Biomedical Ltd Embryo implantation
GB201517523D0 (en) 2015-10-05 2015-11-18 Ostara Biomedical Ltd Methods and compositions for managing reproduction
TW202313678A (zh) 2017-01-20 2023-04-01 法商賽諾菲公司 抗TGF-β抗體及其用途
TWI788321B (zh) * 2017-01-20 2023-01-01 美商健臻公司 骨靶向抗體
JP7104929B2 (ja) * 2017-07-24 2022-07-22 テルモ株式会社 医療用タンパク質とポリアミノ酸とを含む複合体の製造方法および医療用タンパク質とポリアミノ酸とを含む複合体
IL267923B2 (en) * 2018-08-02 2023-06-01 Grifols Worldwide Operations Ltd The composition containing the most concentrated alpha-1 type protein inhibitor and a method for obtaining it

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2538018A (en) * 1944-04-04 1951-01-16 Nordisk Insulinlab Crystalline product of insulin and alkaline protein and process of making it
GB643268A (en) * 1944-04-04 1950-09-15 Nordisk Insulinlab Improved process for the preparation of prolonged effect insulin products
IL79681A (en) * 1985-08-12 1991-06-10 Int Minerals & Chem Corp Transition metal complexes of growth hormones and their prolonged release compositions
PH23446A (en) * 1986-10-20 1989-08-07 Novo Industri As Peptide preparations
US4853218A (en) * 1987-02-24 1989-08-01 Schering Corporation Zinc-protamine-alpha interferon complex
US5084350A (en) * 1990-02-16 1992-01-28 The Royal Institution For The Advance Of Learning (Mcgill University) Method for encapsulating biologically active material including cells
NL9000634A (nl) * 1990-03-20 1991-10-16 Catharina Ziekenhuis Stichting Suspensie-injectiepreparaat op waterbasis, werkwijze voor de bereiding daarvan en toepassing van dit preparaat voor pijnbestrijding.
EP0454044B1 (de) * 1990-04-25 1995-12-06 Hoechst Aktiengesellschaft Pharmakologische Zubereitung, enthaltend Polyelektrolytkomplexe in mikropartikulärer Form und mindestens einen Wirkstoff
CA2084406A1 (en) * 1990-06-04 1991-12-05 Paul Reichert Method for preparing interferon alpha-2 crystals
DK168790D0 (es) * 1990-07-13 1990-07-13 Novo Nordisk As
DE4132005A1 (de) * 1991-09-26 1993-04-01 Merck Patent Gmbh Kombination enthaltend wachstumsfaktoren und polyelektrolyte
RO111990B1 (ro) * 1991-12-20 1997-04-30 Novo Nordisk As Preparate farmaceutice, continand un hormon de crestere sau un derivat al acestuia, si procedeu de preparare
US5198422A (en) * 1992-06-11 1993-03-30 Smithkline Beecham Corporation Stabilized somatotropin for parenteral administration
CZ296649B6 (cs) * 1993-02-23 2006-05-17 Genentech, Inc. Zpusob výroby stabilizovaného polypeptidového prostredku zahrnující stabilizování polypeptidu protidenaturaci organickými rozpoustedly, jeho príprava a prostredek pro regulované uvolnování polypeptidu
HU225496B1 (en) * 1993-04-07 2007-01-29 Scios Inc Pharmaceutical compositions of prolonged delivery, containing peptides
US6284727B1 (en) * 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
DK72793D0 (da) * 1993-06-21 1993-06-21 Novo Nordisk As Nyt produkt
US5439643A (en) * 1993-11-03 1995-08-08 Liebert; Richard T. Method and apparatus for terminal sterilization
US6004549A (en) * 1994-12-14 1999-12-21 Schering Corporation Crystalline protein controlled release compositions
US5788959A (en) * 1995-04-24 1998-08-04 University Of Maryland, Baltimore County Drug delivery device and method for employing the same
US5972331A (en) * 1995-12-22 1999-10-26 Schering Corporation Crystalline interferon alpha for pulmonary delivery and method for producing the same
US7276251B2 (en) * 1997-04-01 2007-10-02 Lg Life Sciences, Ltd., Inc. Sustained-release composition of drugs encapsulated in microparticles of hyaluronic acid
US5932212A (en) * 1996-05-24 1999-08-03 Altus Biologics, Inc. Crosslinked protein crystal formulations and their use as catalysts in organic solvents
US5968895A (en) * 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
EP0954282B1 (en) * 1997-01-16 2005-01-19 Massachusetts Institute Of Technology Preparation of particles for inhalation
US6140475A (en) * 1997-04-11 2000-10-31 Altus Biologics Inc. Controlled dissolution crosslinked protein crystals
DK1009759T3 (da) * 1997-09-05 2008-08-04 Altus Pharmaceuticals Inc Carbohydrat-tværbundne glycoproteinkrystaller
US6380357B2 (en) * 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals
US6541606B2 (en) * 1997-12-31 2003-04-01 Altus Biologics Inc. Stabilized protein crystals formulations containing them and methods of making them
JP4965022B2 (ja) * 1998-04-27 2012-07-04 アルタス ファーマシューティカルズ インコーポレイテッド 安定化されたタンパク質結晶、それを含む処方物、およびそれを作製する方法
US6417237B1 (en) * 2000-06-08 2002-07-09 The Board Of Trustees Of The University Of Illinois Macromolecular drug complexes and compositions containing the same
US7037889B2 (en) * 2000-09-13 2006-05-02 Praecis Pharmaceuticals Inc. Pharmaceutical compositions for sustained drug delivery
MXPA03005135A (es) * 2000-12-13 2003-12-04 Lilly Co Eli Regimen de tratamiento cronico usando peptidos insulinotropicos similares al glucagon.
EP2325205A3 (en) * 2000-12-28 2011-10-12 Altus Pharmaceuticals Inc. Crystals of whole antibodies and fragments thereof and methods for making and using them
EP1448222A4 (en) * 2001-10-19 2006-05-17 Lilly Co Eli BIPHASIC MIXTURES OF GLP-1 AND INSULIN
DE60237841D1 (de) * 2001-11-13 2010-11-11 Genentech Inc Zusammensetzungen basierend auf APO2-Ligand/ TRAIL und ihre Verwendung
DK1581251T3 (da) * 2002-12-31 2016-06-27 Althea Tech Inc Krystaller af humant væksthormon og fremgangsmåder til fremstilling deraf

Also Published As

Publication number Publication date
NZ571243A (en) 2010-04-30
ZA200505306B (en) 2006-09-27
BR0317896A (pt) 2005-12-06
JP2010174036A (ja) 2010-08-12
KR20050094832A (ko) 2005-09-28
CA2512001A1 (en) 2004-07-22
NZ554885A (en) 2009-07-31
EP1585771A4 (en) 2006-11-29
US20060008532A1 (en) 2006-01-12
EP1585771A1 (en) 2005-10-19
MXPA05007182A (es) 2006-04-07
JP2006523609A (ja) 2006-10-19
WO2004060920A1 (en) 2004-07-22
AU2003300126A1 (en) 2004-07-29
AU2003300126B2 (en) 2010-04-01

Similar Documents

Publication Publication Date Title
CO5640146A2 (es) Complejos de cristales de proteina y polimeros ionicos
JP2022020674A5 (es)
EP1819830B1 (en) Methods for antibody engineering
DE68926882T2 (de) Plasmidvektor mit pectatlyase-signalsequenz
KR900701836A (ko) 신규 hiv 단백질 및 aids의 진단, 예방 또는 치료에 유용한 펩티드
RU2022102624A (ru) Композиции и способы для соединения внеклеточных доменов типа i и типа ii в качестве гетерологичных химерных белков
Grossberg et al. The neutralization of interferons by antibody. I. Quantitative and theoretical analyses of the neutralization reaction in different bioassay systems
DE122007000078I2 (de) CTL4A-Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendung
RU2004117915A (ru) Модифицированное анти-tnf альфа антитело
CN101445559A (zh) 三聚体可溶抗体与其产生及使用的方法
CA2212702A1 (en) Mucosal vascular addressins and uses thereof
Skerritt et al. Specificity characteristics of monoclonal antibodies to wheat grain storage proteins
JP2013511966A5 (es)
Chrétien et al. A monoclonal anti-IgE antibody against an epitope (amino acids 367-376) in the CH3 domain inhibits IgE binding to the low affinity IgE receptor (CD23).
CA2233207A1 (en) Type cc chemokine-like protein
RU94046414A (ru) Моноклональные антитела к гликопротеину р, их получение и применение, продуцирующие их клетки, иммунологический диагностический набор на их основе, терапевтический состав
EP0462623A1 (en) Monoclonal antibodies to human immune interferon
CN117110492A (zh) 鉴别蛋白质中的游离巯基的方法
RU2018103173A (ru) Гетеромеры, содержащие слитые белки доменов антител
Goding et al. Structure of the murine plasma cell alloantigen PC-1: comparison with the receptor for transferrin.
Warner Neoplasms of immunoglobulin-producing cells in mice
Marks et al. Characterization of two epitopes on insulin using monoclonal antibodies
CN103343134B (zh) EGF-Fc融合蛋白及其哺乳动物表达体系高表达生产方法
KR960001122A (ko) 재조합 단일사슬 Fv 항체 절편과 B형 간염 바이러스 표면 항원의 면역정제를 위한 그 용도
AU2019266042A1 (en) Artificial protein containing an antibody antigen-binding region, fused with bioactive peptides

Legal Events

Date Code Title Description
FC Application refused